Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 975-979

  Iwase, Yuko ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Antitumor effect; Everolimus; Liposome; Mammalian target of rapamycin inhibitor; Small lung cell carcinoma

Indexed keywords

DISTEAROYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; EVEROLIMUS; GLYCEROPHOSPHOLIPID; IRINOTECAN; LIPOSOME; MACROGOL 2000; OCTREOTIDE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; SIROLIMUS; THYROID NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861906379     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.975     Document Type: Article

References (20)

1. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer, 4, 335-348 (2004).
2. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol., 16, 525-537 (2005).
3. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-430 (2006).
4. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther., 82, 381-388 (2007).
5. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V, Venuta S, Romano MF. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood, 106, 1400-1406 (2005).
6. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene, 26, 2255-2262 (2007).
7. Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 105, 2527-2534 (2005).
8. LC Laboratories 〈http://www.lclabs.com/prodfile/D-F/E-4040. php4〉, cited November 2, 2011.
9. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant. Proc., 28, 970-973 (1996).
10. Rouf MA, Vural I, Renoir JM, Hincal AA. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res., 19, 322-331 (2009).
11. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer Ther., 9, 963-975 (2010).
12. Shin HC, Alani AWG, Cho H, Bae Y, Kolesar JM, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm., 8, 1257-1265 (2011).
13. Iwase Y, Maitani Y. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts. Cancer Sci., 103, 310-316 (2012).
14. Swarbrick J. Liposomes as pharmaceutical dosage forms to microencapsulation. Encyclopedia of Pharmaceutical Technology. (Swarbrick J, Boylan JC ed.) Vol. 9, Marcel Dekker, New York (1993).
15. Arai H, Suzuki T, Kaseda C, Ohyama K, Takayama K. Bootstrap re-sampling technique to evaluate the optimal formulation of theophylline tablets predicted by non-linear response surface method incorporating multivariate spline interpolation. Chem. Pharm. Bull., 55, 586-593 (2007).
16. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Patents Anticancer. Drug Discov., 5, 29-57 (2010).
17. Niu H, Wang J, Li H, He P. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of surviving in lung cancer cells. J. Exp. Clin. Cancer Res., 30, 28-35 (2011).
18. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392-395 (2009).
19. Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia- inducible factor-1α axis. Clin. Cancer Res., 15, 1297-1307 (2009).
20. Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia, 13, 217-229 (2011).